Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Molecule Called YS-ON-001 Attracted Attention for Pancreatic Cancer Treatment

A New Molecule Called YS-ON-001 Attracted Attention for Pancreatic Cancer Treatment

On 26 February 2018, the United States Food and Drug Administration (FDA) was announced to be supporting a different, next-generation immunotherapy agent for pancreatic cancer, the molecule YS-ON-001 .

Pancreatic cancer, although not among the most common cancers, is the 5th leading cause of cancer death. Over the past 50 years, the discovery first of targeted drugs and then immunotherapies has significantly improved survival in many cancers, but these advances have had little impact on pancreatic cancer treatment. The most important reasons are the pancreas’s location and pancreatic cancer’s highly complex tumor microenvironment. Every advance in pancreatic cancer treatment is therefore extremely important.

YS-ON-001 is a biological product developed to regulate the immune system (immunomodulation). It has a broad spectrum of activity on the immune system.

YS-ON-001 is an immunotherapy product with multiple actions altering the tumor microenvironment: triggering special immune substances against tumors (antitumor cytokines), activating natural killer cells, regulating macrophages and suppressing regulatory T cells.

The agent is thought to have potential for use alone or combined with chemotherapy, targeted therapies and other immunotherapies.

YS-ON-001 demonstrated effectiveness in animal studies in tumors of many organs, including breast, lung, liver and pancreas. Animal toxicology studies also showed a favorable safety profile.

Other Topics You May Be Interested In:

Sources

FDA Grants Orphan Drug Designation to YS-ON-001 for the Treatment of Pancreatic Cancer.
By The ASCO Post

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Molecule Called YS-ON-001 Attracted Attention for Pancreatic Cancer Treatment

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy